Soluble pd-l1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer

HIGHLIGHTS

• who: Yinjun He from the The study enrolled a total of , patients (Fig1) admitted to the Department of Colorectal Surgery of First Affiliated Hospital, Zhejiang University School of Medicine, China, from December , to August, . Sixtyeight patients who were primarily diagnosed with stage, III CRC and underwent radical surgery, together with , patients with pMMR metastatic colorectal cancer (mCRC), were included in our study. Another , patients with refractory pMMR CRC, who received regorafenib combined with sintilimab, a , inhibitor, were also enrolled in our study. To fully assess the dynamic changes in sPD-, levels during treatment, plasma samples from patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.